Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Novo Holdings, which controls obesity drugmaker Novo Nordisk, is sharpening its focus on India, targeting single-specialty ...

Novo Holdings, which controls obesity drugmaker Novo Nordisk, is sharpening its focus on India, targeting single-specialty ...

A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli ...

Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. Learn more about NVO stock here.

Earlier today, Novo Nordisk A/S announced that it has called for an extraordinary general meeting to elect new members to its ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Novo Nordisk to reshuffle its board after a clash with its largest shareholder over governance changes. Read more here.

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has ...

Shares of Novo Nordisk have dropped as the company's largest investor, Novo Nordisk Foundation, calls for a board overhaul.

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive ...